762 related articles for article (PubMed ID: 28699367)
1. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
2. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
3. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
Zheng YC; Yu B; Chen ZS; Liu Y; Liu HM
Epigenomics; 2016 May; 8(5):651-66. PubMed ID: 27102879
[TBL] [Abstract][Full Text] [Related]
4. Expanding the Role of the Histone Lysine-Specific Demethylase LSD1 in Cancer.
Majello B; Gorini F; Saccà CD; Amente S
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30866496
[TBL] [Abstract][Full Text] [Related]
5. LSD1: Expanding Functions in Stem Cells and Differentiation.
Martinez-Gamero C; Malla S; Aguilo F
Cells; 2021 Nov; 10(11):. PubMed ID: 34831474
[TBL] [Abstract][Full Text] [Related]
6. LSD1: biologic roles and therapeutic targeting.
Maiques-Diaz A; Somervaille TC
Epigenomics; 2016 Aug; 8(8):1103-16. PubMed ID: 27479862
[TBL] [Abstract][Full Text] [Related]
7. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
[TBL] [Abstract][Full Text] [Related]
8. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
9. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
10. Targeting Histone Lysine Demethylase LSD1/KDM1A as a New Avenue for Cancer Therapy.
Fang Y; Liao G; Yu B
Curr Top Med Chem; 2019; 19(11):889-891. PubMed ID: 31389779
[No Abstract] [Full Text] [Related]
11. Targeting the LSD1/KDM1 Family of Lysine Demethylases in Cancer and Other Human Diseases.
Mao F; Shi YG
Adv Exp Med Biol; 2023; 1433():15-49. PubMed ID: 37751134
[TBL] [Abstract][Full Text] [Related]
12. Expression, Purification, and Biochemical Analysis of the LSD1/KDM1A Histone Demethylase.
Laurent B; Shi Y
Methods Enzymol; 2016; 573():241-59. PubMed ID: 27372756
[TBL] [Abstract][Full Text] [Related]
13. Annual review of LSD1/KDM1A inhibitors in 2020.
Fu DJ; Li J; Yu B
Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of epithelial to mesenchymal transition by the Lysine-specific demethylase LSD1/KDM1A.
Ambrosio S; Saccà CD; Majello B
Biochim Biophys Acta Gene Regul Mech; 2017 Sep; 1860(9):905-910. PubMed ID: 28720390
[TBL] [Abstract][Full Text] [Related]
15. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
16. Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells.
Hino S; Kohrogi K; Nakao M
Cancer Sci; 2016 Sep; 107(9):1187-92. PubMed ID: 27375009
[TBL] [Abstract][Full Text] [Related]
17. Histone methyl-transferases and demethylases in the autophagy regulatory network: the emerging role of KDM1A/LSD1 demethylase.
Ambrosio S; Ballabio A; Majello B
Autophagy; 2019 Feb; 15(2):187-196. PubMed ID: 30208749
[TBL] [Abstract][Full Text] [Related]
18. LSD1 inhibition: a therapeutic strategy in cancer?
Lynch JT; Harris WJ; Somervaille TC
Expert Opin Ther Targets; 2012 Dec; 16(12):1239-49. PubMed ID: 22957941
[TBL] [Abstract][Full Text] [Related]
19. Promising natural lysine specific demethylase 1 inhibitors for cancer treatment: advances and outlooks.
Li ZR; Gu MZ; Xu X; Zhang JH; Zhang HL; Han C
Chin J Nat Med; 2022 Apr; 20(4):241-257. PubMed ID: 35487595
[TBL] [Abstract][Full Text] [Related]
20. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy.
Romo-Morales A; Aladowicz E; Blagg J; Gatz SA; Shipley JM
Pediatr Blood Cancer; 2019 Sep; 66(9):e27888. PubMed ID: 31207107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
